Literature DB >> 2850311

Abnormal responses to vasoactive intestinal peptide and corticotropin releasing hormone during the spontaneous remission of Cushing's disease.

S Cannavò1, L Li Calzi, A Aragona, F Trimarchi.   

Abstract

Abnormalities in hypothalamic-pituitary adrenal axis function were demonstrated by measuring plasma adrenocorticotropin abnormal concentrations following Vasoactive Intestinal Peptide (VIP) and Corticotropin Releasing Hormone (CRH) administration during a phase of remission of Cushing's disease in a 45-year-old female patient. When observed 80 days after the first examination, the patient no longer showed cushingoid features and serum cortisol and plasma ACTH were not abnormally high. VIP infusion (75 micrograms during 12 min) induced a significant increase in serum cortisol and ACTH plasma levels with respect to the normal unresponsiveness. Exaggerated plasma ACTH response to CRH (50 micrograms iv) was also observed. We conclude that the study of ACTH and cortisol response to VIP and CRH may be useful in revealing Cushing's disease even during a remission phase of the disorder.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2850311     DOI: 10.1007/BF03349075

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  10 in total

1.  Spontaneous remission of Cushing's syndrome in a patient with an adrenal adenoma.

Authors:  N Blau; W E Miller; E R Miller; S J Cervi-Skinner
Journal:  J Clin Endocrinol Metab       Date:  1975-04       Impact factor: 5.958

2.  Cyclical Cushing's Syndrome.

Authors:  C P Aber; H D Cheetham
Journal:  Br Med J       Date:  1961-02-04

3.  Cyclical Cushing's disease: two distinct rhythms in a patient with a basophil adenoma.

Authors:  A B Atkinson; A Chestnutt; E Crothers; R Woods; J A Weaver; L Kennedy; B Sheridan
Journal:  J Clin Endocrinol Metab       Date:  1985-02       Impact factor: 5.958

4.  Cushing's disease with periodic hormonogenesis: one explanation for paradoxical response to dexamethasone.

Authors:  R D Brown; G R Van Loon; D N Orth; G W Liddle
Journal:  J Clin Endocrinol Metab       Date:  1973-03       Impact factor: 5.958

5.  Cyclical Cushing's disease: report of a case cured by conventional cobaltotherapy.

Authors:  M L De Feo; L Bonfanti; S Romano; S Fusi; G Giusti; G Messeri; G Forti
Journal:  J Endocrinol Invest       Date:  1987-02       Impact factor: 4.256

6.  Intermittent Cushing's disease with spontaneous remission.

Authors:  R S Scott; E A Espiner; R A Donald
Journal:  Clin Endocrinol (Oxf)       Date:  1979-11       Impact factor: 3.478

7.  Adrenocorticotropin and cortisol responsiveness to thyrotropin-releasing hormone and luteinizing hormone-releasing hormone discloses two subsets of patients with Cushing's disease.

Authors:  G F Pieters; A G Smals; H J Goverde; G J Pesman; E Meyer; P W Kloppenborg
Journal:  J Clin Endocrinol Metab       Date:  1982-12       Impact factor: 5.958

8.  Dynamics of adrenocorticotropin (ACTH) secretion in cyclic Cushing's syndrome: evidence for more than one abnormal ACTH biorhythm.

Authors:  R M Jordan; A Ramos-Gabatin; J W Kendall; D Gaudette; R C Walls
Journal:  J Clin Endocrinol Metab       Date:  1982-09       Impact factor: 5.958

9.  Vasoactive intestinal peptide stimulates adrenocorticotropin release from human corticotropinoma cells in culture: interaction with arginine vasopressin and hydrocortisone.

Authors:  M C White; E F Adams; M Loizou; K Mashiter
Journal:  J Clin Endocrinol Metab       Date:  1982-11       Impact factor: 5.958

10.  Tests of prolactin secretion in diagnosis of prolactinomas.

Authors:  E A Cowden; J G Ratcliffe; J A Thomson; P Macpherson; D Doyle; G M Teasdale
Journal:  Lancet       Date:  1979-06-02       Impact factor: 79.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.